Feature | Women's Health | November 11, 2015

Cutting the Cost of Breast Cancer Treatment

How two Fayetteville, Ark., medical groups found success in pioneering use of an absorbable, 3-D marker used during treatment for breast cancer

Cutting the Cost  of Breast Cancer Treatment

Breast surgeon Michael Cross, M.D., has done clinical research on the DotMed BioZorb surgical marker. (Photo courtesy of DotMed)

Breast cancer research conducted by two Fayetteville, Ark., medical groups highlights their success in pioneering use of an absorbable, three-dimensional marker used during treatment for breast cancer. Their cost analysis showed that by helping to shorten the course of radiation treatments, the surgical marker contributed to a 25 percent cost savings per patient.

Breast surgeon Michael Cross, M.D., of Breast Treatment Associates, and colleagues at Highlands Oncology Group compiled three years of data on use of the BioZorb marker from Focal Therapeutics as part of improvements in treating breast cancer. They concluded that this unique device assisted with the targeting of radiation treatments, which are usually needed after breast cancer surgery.

A Targeted Approach

The surgeon sutures the marker directly to the area that needs radiation. With the marker providing greater confidence in targeting, the doctors said they were able to use shorter courses of radiation — an approach often referred to as hypofractionated therapy.

Hypofractionated radiation treatments typically can be given over three to five weeks, compared to the usual five to seven weeks required for standard radiation therapy.

Recent studies have indicated this shorter course of treatment significantly lowers treatment costs and is just as effective in overall survival rates and preventing cancer recurrence. It also has been shown to lower toxicity and improve patients’ quality of life measures. 

Important Trends

The ability to provide radiation with equivalent success in a shorter timeframe is an important and growing trend around the world. However, adoption of these methods has previously been hindered by the difficulty in confidently defining the surgical site needing radiation.

The Fayetteville researchers’ scientific poster, which was presented at the 2015 Breast Cancer Symposium in San Francisco, summarized prospective research and clinical experience with 109 patients over three years.

BioZorb is a small coil, inserted into the breast by the surgeon at the time of tumor removal. It holds six tiny clips arranged in a three-dimensional array. This 3-D array remains over time, while the coil holding the clips dissolves.

The marker helps clinicians visualize where the tumor was removed. It can also be used to help plan and target radiation treatments done after surgery, while marking the cancer site for follow-up mammograms and other imaging studies.

“This device helps us provide shorter courses of radiation, which means less travel and time commitment for patients and is therefore much more convenient for them,” Cross said. “We are also seeing better cosmetic outcomes using this device. Because it provides a structure for the breast tissue during the healing process, it supports regrowth of healthy tissue and helps preserve the natural contour of the breast after surgery.”

Targeted Radiation

Arnold Smith, M.D., a radiation oncologist at Highlands Oncology Group who contributed to the research, said the marker “lets us clearly see where the surgeon removed the tumor, which is the spot with the greatest risk for cancer recurrence. This way, we can focus the radiation where it needs to be. That means more efficient treatment and better care for our patients.”

Scott Jones, M.S., D.A.B.R, the medical physicist at Highlands Oncology, said the device makes it easier during radiation treatment to use more sophisticated “field in field planning.” He said BioZorb also contributes to cost savings from a shorter course of radiation treatment by adding a level of confidence about the accuracy of where the radiation beam in each dose “fraction” should be aimed especially for partial breast or boost treatments.

“When you are delivering radiation with fewer fractions, you need to be sure you know exactly where the dose should be delivered, “ he said. “What BioZorb allows us to do with more confidence is to delineate the breast region more accurately within the field, to contour the dose in three dimensions and deliver each treatment very accurately.” 

Cross and his colleagues were the first in the United States to make the surgical marker available to patients. Their research on its use is the most extensive to date.

Editor’s note: More information on this research can be found at www.breasttreatment.com.

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
Feature | Breast Imaging | November 07, 2018 | By Jeff Zagoudis
Breast imaging technology has experienced major growth over the last decade or so, and a new report suggests the mark
Philips’ Compressed SENSE technology helps shorten MRI exams by eliminating redundant radiofrequency signals from the acquisition phase. The software reconstructs any missing  information to maintain high image quality. (Images courtesy of Philips/University Hospital Cologne)

Philips’ Compressed SENSE technology helps shorten MRI exams by eliminating redundant radiofrequency signals from the acquisition phase. The software reconstructs any missing information to maintain high image quality. (Images courtesy of Philips/University Hospital Cologne)

Feature | Breast Imaging | November 05, 2018 | By Jeff Zagoudis
The incidence of breast cancer is rising globally, with an estimated 1 in 8 women diagnosed in their lifetime and 40,...
Deaconess Health System Chooses Sectra as Enterprise Imaging Vendor
News | Enterprise Imaging | November 02, 2018
International medical imaging information technology (IT) and cybersecurity company Sectra will install its enterprise...
Volpara Enterprise Cloud Reaches 1 Million Mammograms Stored
News | Mammography | October 31, 2018
Volpara Solutions announced that the data stored in the Volpara Enterprise cloud now exceeds 1 million mammographic...
Etta Pisano Named American College of Radiology Chief Research Officer
News | Radiology Business | October 25, 2018
October 25, 2018 — Breast imaging research pioneer Etta Pisano, M.D., FACR, has been named...
DenseBreast-info.org Launches Patient Education Video Series
News | Breast Density | October 24, 2018
DenseBreast-info.org (DB-I) announced the release of "Let's Talk About Dense Breasts," a series of three informational...
Fewer, larger individual doses of radiation lead to similar adverse effects to normal tissue after 10 years as with conventional radiation therapy for early breast cancer
News | ASTRO | October 22, 2018
In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer,
DCIS, ductal carcinoma in situ, radiation therapy, survival benefit, Brigham and Women's Hospital study. #ASTRO2018 #ASTRO #ASTRO18

Image courtesy of Barco

News | ASTRO | October 21, 2018
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservatio